Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.
| Current Price | ₹1,646.95 |
|---|---|
| Market Cap | ₹0 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Health Care; Pharmaceuticals, Biotechnology and Life Sciences; Pharmaceuticals; Pharmaceuticals; Pharmaceutical Products; Anti-infective Drugs; Antifungal Drugs; Antiviral Drugs; Oncology Drugs |
| P/E Ratio | 28.8 |
| 52-Week Range | ₹1,067.00 – ₹1,774.00 |
| Dividend Yield | 0.09% |
1. Pharmaceutical-100%
HALEOS LABS LIMITED is trading at ₹1,646.95, with a market capitalisation of ₹0 Cr.
HALEOS LABS LIMITED operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Health Care; Pharmaceuticals, Biotechnology and Life Sciences; Pharmaceuticals; Pharmaceuticals; Pharmaceutical Products; Anti-infective Drugs; Antifungal Drugs; Antiviral Drugs; Oncology Drugs).
HALEOS LABS LIMITED has a P/E of 28.8.